Munchkin Revolutionizes Breastfeeding Support with Groundbreaking Innovation Backed by New Clinical Research
Munchkin Inc. ('Munchkin'), the most loved baby lifestyle brand in the world, owned by WHY Brands Inc. ('WHY'), today announced in conjunction with National Breastfeeding Awareness Month and World Breastfeeding Week, the completion of new groundbreaking clinical research that supports how Munchkin's Flow Nipple Shield+ is changing lives, empowering breastfeeding journeys and helping moms achieve their nursing goals with unprecedented success.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804861459/en/
Munchkin announces new groundbreaking research during National Breastfeeding Awareness Month, showing how its Flow Nipple Shield+ is revolutionizing breastfeeding success.
According to Munchkin's recently completed U.S. clinical research study* of approximately 300 moms, the Flow Nipple Shield+ achieved remarkable results and showcased a paradigm shift in breastfeeding support, including:
'Flow Nipple Shield+ represents a significant breakthrough in maternal health technology,' says Dr. Mona Amin, Board Certified Pediatrician and International Board-Certified Lactation Consultant. 'By removing the guesswork and offering real-time reassurance, it's a powerful tool to build confidence and strengthen mothers' trust in their own abilities while delivering measurable impact on breastfeeding success rates. This innovation could help reshape national maternal health outcomes by making a meaningful difference for families wanting to continue their breastfeeding journey.'
What sets this innovation apart is its first-to-market visual confirmation technology. Flow Nipple Shield+ features a unique channel that allows parents to actually see milk transfer during feeding – addressing one of the most common anxieties new mothers face. Made with 100% food-grade silicone and packaged in a convenient travel-friendly steam sterilizer case, Flow Nipple Shield+ is designed to support better latch, confirm milk transfer and reduce postpartum stress.
'We know that feeding doesn't look the same for everyone and that's okay,' said Kristin Pagano, GM Infant Nutrition at Munchkin and mom of two. 'The Flow Nipple Shield+ was created to offer compassionate, judgement-free support for parents navigating the ups and downs of feeding. This month, we're proud to make it even more accessible because every parent deserves the right to feel confident, capable and supported in how they nourish their baby.'
Beyond individual families, Munchkin is committed to making a broader impact. The company has donated more than $100,000 worth of Flow Nipple Shield+ units to WIC (Special Supplemental Nutrition Program for Women, Infants, and Children) chapters throughout the U.S. this year ensuring that underserved families across the country have access to this game-changing support. WIC is a division of the USDA's Food & Nutrition Services that provides breastfeeding support, touching more than 43% of births in the U.S. with its services.
The Munchkin Flow Nipple Shield+ Starter Kits (shield, cleaning syringe, and travel case) retails for $39.99 at Munchkin.com, Walmart, Target and Amazon. This August, Munchkin is making it even more accessible by offering a FREE Flow Replacement Kit (brand-new nipple shield and a travel case that doubles as a steam sterilizer) with every Flow Nipple Shield+ purchase.
To learn more about Munchkin and first account testimonials from moms using Flow, please visit munchkin.com, munchkin.com/flow or follow us on Facebook and Instagram.
About Munchkin Inc.
For more than 30 years, Munchkin Inc., the baby lifestyle brand owned by WHY Brands Inc, has produced innovative products and functional gear for children and their caregivers. Munchkin has 350+ patents to date, and more than 250 international product and brand design awards. Munchkin products are sold in more than 50 countries and have received over 1.45 million five-star reviews.
Munchkin has been awarded Great Place to Work for four consecutive years and is recognized as a 2024 Best Places to Work by Built In. Munchkin has been honored on Fast Company's annual 'Brands That Matter' list for two consecutive years, including 2024, and ranked number eight on Fortune's list of 'Most Innovative Companies' in 2023.
As the only baby brand in the United Nations Global Compact, the company prioritizes corporate social responsibility with commitments to environmental protection and animal welfare, which are highlighted in its annual Sustainability Report. Learn more at www.WHYBrands.com and www.Munchkin.com.
About WHY Brands Inc.
WHY is a portfolio of brands that invent, develop, and design creative products across an array of categories. With every new idea and undertaking, we ask and end with WHY. That spirit of inquiry drives our commitment to innovation, highlighted by 350+ patents to date. We believe great ideas and next-generation design can be lifechanging. WHY's portfolio includes baby lifestyle brand Munchkin and Curio Home Goods. Learn more at www.WHYBrands.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250804861459/en/
CONTACT: Media Contact
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: RETAIL CONSUMER HOME GOODS WOMEN BABY/MATERNITY SPECIALTY
SOURCE: Munchkin Inc.
Copyright Business Wire 2025.
PUB: 08/04/2025 08:30 AM/DISC: 08/04/2025 08:30 AM
http://www.businesswire.com/news/home/20250804861459/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
eHealth (EHTH) Q2 Earnings Report Preview: What To Look For
Online health insurance comparison site eHealth (NASDAQ:EHTH) will be reporting results this Wednesday morning. Here's what to expect. eHealth beat analysts' revenue expectations by 13.4% last quarter, reporting revenues of $113.1 million, up 21.7% year on year. It was an exceptional quarter for the company, with a solid beat of analysts' EBITDA estimates and full-year EBITDA guidance exceeding analysts' expectations. It reported 1.16 million users, down 1.8% year on year. Is eHealth a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting eHealth's revenue to decline 29.5% year on year to $46.41 million, a further deceleration from the 1.4% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$1.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. eHealth has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 13.1% on average. Looking at eHealth's peers in the online marketplace segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Shutterstock delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 7.5%, and EverQuote reported revenues up 33.7%, in line with consensus estimates. Shutterstock's stock price was unchanged following the results. Read our full analysis of Shutterstock's results here and EverQuote's results here. Investors in the online marketplace segment have had steady hands going into earnings, with share prices up 1.5% on average over the last month. eHealth is down 22.5% during the same time and is heading into earnings with an average analyst price target of $10 (compared to the current share price of $3.21). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
38 minutes ago
- Yahoo
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution's MyDataHelps® platform ANN ARBOR, Mich., August 05, 2025--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. "Decentralized trials broaden reach, speed timelines and yield richer real-world evidence," said Vik Kheterpal, MD, a principal at CareEvolution. "LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid." Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. "For people with severe Long Covid, travel can be dangerous," said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. "LoCITT enables even patients with the most severe symptoms to join the search for answers." Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. "We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it," said John Redd, CEO of SILC. "We're hopeful that a remote trial will help us find effective treatments more quickly." CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at View source version on Contacts CareEvolutionpr@ Swati Pandey, SILCspandey@ Anna Andersen, Scripps Researchaanders@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
These 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says
These 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says originally appeared on Men's Fitness. Carbs are not the root of all evil. But when you're in a calorie deficit, they can feel off-limits. The truth is, carbs are the body's main source of fuel. They power our heavy lifting days, energize outdoor runs, and sustain us through everyday life. Still, some carb-heavy foods like bread can be calorie-dense and feel like a trap when you're trying to cut back. Trainer Dan Go shared five low-calorie carb sources that actually help keep you full while you're in a Carbs Potatoes "Potatoes are low in calories, high in fiber—especially with the skin. This makes them incredibly filling, and also their resistant starch and high water content helps you feel satisfied longer," Go says. Blueberries Blueberries may not be the first food that comes to mind when thinking about carbs. But, with their rich fiber and water content, they're a low-calorie carb that's highly satiating. The fiber in blueberries also slows digestion, which keeps you full and helps stabilize blood sugar. Lentils Lentils are small, but their fiber content is mighty. Along with its carb content, they're also a great source of plant protein, high in satiety. Broccoli "The reason I love broccoli is because it's one of the perfect foods to volumize your meals, because it contains a lot of fiber, a lot of water, and it helps you keep full while giving you an incredible nutrient profile," Go says. Rich in vitamin C, K, and folate, eating broccoli helps support your metabolism and digestion. Apples Go calls apples "nature's appetite suppressant." If you need a sweet treat during your calorie deficit, lean on apples. They're high in fiber and low in calories, helping you curb hunger and reduce snacking. Apples are also rich in 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says first appeared on Men's Fitness on Jul 10, 2025 This story was originally reported by Men's Fitness on Jul 10, 2025, where it first appeared. Solve the daily Crossword
